论文部分内容阅读
目的探讨基质金属蛋白酶MMP9在胰腺癌组织中的表达及其临床意义。方法采用免疫组织化学技术检测MMP9在11例正常胰腺组织和88例胰腺癌组织中的表达。结果免疫组织化学结果显示胰腺癌组织中MMP9的表达显著高于正常组织(P<0.01)。MMP9的表达和胰腺癌的临床TNM分期、淋巴结转移均成正相关(均P<0.01),与生存时间成负相关(P<0.01),而与肿瘤部位和病理分级均无关(均P>0.05)。经COX回归分析显示MMP9表达与胰腺癌预后成负相关(P<0.01)。结论 MMP9在胰腺癌的发生、发展和转移中扮演着重要角色,在治疗过程中对其进行检测有助于对胰腺癌患者的预后进行评估。
Objective To investigate the expression of MMP9 in pancreatic cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression of MMP9 in 11 normal pancreatic tissues and 88 pancreatic cancer tissues. Results Immunohistochemistry showed that the expression of MMP9 in pancreatic cancer tissues was significantly higher than that in normal tissues (P <0.01). There was a positive correlation between the expression of MMP9 and the clinical TNM stage and lymph node metastasis (all P <0.01), but not with the tumor location and pathological grade (all P> 0.05) . COX regression analysis showed that the expression of MMP9 was negatively correlated with the prognosis of pancreatic cancer (P <0.01). Conclusion MMP9 plays an important role in the development, progression and metastasis of pancreatic cancer. It is helpful to evaluate the prognosis of patients with pancreatic cancer during the course of treatment.